On June 5th, 2021, Westlake Omics (Hangzhou) Biotechnology Co., Ltd. signed a Memorandum of Understanding (MoU) with Thermo Fisher Scientific Inc. (hereinafter referred to as Thermo Fisher), concerning the establishment of a joint lab located in Hangzhou and therefore facilitating a series of collaborations in Application Fields of Clinical Proteomic in Translational Medicine.
It is the mutual attention drawn on the threat such major human diseases as tumours have posed to human health that has pulled the two parties together for this MoU. As demonstrated by such cancer as thyroid cancer, limited accuracy still comes as a stumbling block as to determine whether a tumor is benign or malignant if merely by traditional methods.
Dr. Tiannan Guo, the founder of Westlake Omics, has shown his high confidence in this partnership, expressing, "This cooperation is conducive to our joint exploration of new diagnostic methods and therapeutic targets that are worth tapping into for clinical application."
Westlake Omics has been facilitating accurate typing, prediction and precise treatment of such critical human diseases as cancer, propped by the integration of AI deep learning with clinical medical big data. To date, Westlake Omics has already made great strides in the precise diagnosis and treatment of such diseases as thyroid nodules by means of detecting protein expression levels in organisms collected from the clinical samples out of clinical cohorts.
Thermo Fisher, with great anticipation over the establishment of this joint laboratory, has pointed out that it is the leading mass spectrometry platform developed by Thermo Fisher and Westlake Omics's expertise in its well-established omics analysis technology that has made such cooperation possible. It is expected that this mutually complementary partnership is to boost the globally clinically-needed precision diagnosis of tumor and other critical diseases by joint efforts in accelerating the intelligent process of omics-assisted diagnosis and launching better and more featured auxiliary diagnosis and treatment solutions.
The on-site inauguration ceremony of this lab is planned to be hosted by the two companies at the Westlake Innovation Center in Hangzhou.
Thermo Fisher Scientific Inc. is dedicated to quality products and services that are beneficial to their clients as they accelerate life sciences research, grapple with issues and challenges confronted in the analytical field, advance medical diagnostics and lift up laboratory productivity.
Westlake Omics (wOmics), founded in July 2020, is committed to making breakthroughs in precision medicine and drug R&D by an unwavering focus on critical issues that impact life and health. This vision is driven by AI-empowered high-throughput proteomic analysis of minute amounts of clinical specimens and Omics technologies, supported by technological innovation and multi-modal big data.
On June 5th, 2021, Westlake Omics (Hangzhou) Biotechnology Co., Ltd. signed a Memorandum of Understanding (MoU) with Thermo Fisher Scientific Inc. (hereinafter referred to as Thermo Fisher), concerning the establishment of a joint lab located in Hangzhou and therefore facilitating a series of collaborations in Application Fields of Clinical Proteomic in Translational Medicine.
It is the mutual attention drawn on the threat such major human diseases as tumours have posed to human health that has pulled the two parties together for this MoU. As demonstrated by such cancer as thyroid cancer, limited accuracy still comes as a stumbling block as to determine whether a tumor is benign or malignant if merely by traditional methods.
Dr. Tiannan Guo, the founder of Westlake Omics, has shown his high confidence in this partnership, expressing, "This cooperation is conducive to our joint exploration of new diagnostic methods and therapeutic targets that are worth tapping into for clinical application."
Westlake Omics has been facilitating accurate typing, prediction and precise treatment of such critical human diseases as cancer, propped by the integration of AI deep learning with clinical medical big data. To date, Westlake Omics has already made great strides in the precise diagnosis and treatment of such diseases as thyroid nodules by means of detecting protein expression levels in organisms collected from the clinical samples out of clinical cohorts.
Thermo Fisher, with great anticipation over the establishment of this joint laboratory, has pointed out that it is the leading mass spectrometry platform developed by Thermo Fisher and Westlake Omics's expertise in its well-established omics analysis technology that has made such cooperation possible. It is expected that this mutually complementary partnership is to boost the globally clinically-needed precision diagnosis of tumor and other critical diseases by joint efforts in accelerating the intelligent process of omics-assisted diagnosis and launching better and more featured auxiliary diagnosis and treatment solutions.
The on-site inauguration ceremony of this lab is planned to be hosted by the two companies at the Westlake Innovation Center in Hangzhou.
Thermo Fisher Scientific Inc. is dedicated to quality products and services that are beneficial to their clients as they accelerate life sciences research, grapple with issues and challenges confronted in the analytical field, advance medical diagnostics and lift up laboratory productivity.
Westlake Omics (wOmics), founded in July 2020, is committed to making breakthroughs in precision medicine and drug R&D by an unwavering focus on critical issues that impact life and health. This vision is driven by AI-empowered high-throughput proteomic analysis of minute amounts of clinical specimens and Omics technologies, supported by technological innovation and multi-modal big data.
